John
The world’s biggest selling drug of all time — the cholesterol medicine Lipitor — goes generic at the end of the month. Will the world’s leading maker of generic drugs be selling no-name Lipitor pills? A lot of tongues are wagging. Lipitor loses U.S. patent protection Nov. 30. Selling generic versions is a big prize, as world-wide brand sales top $10 billion a year. Pfizer plans to keep selling branded Lipitor. And it had reached agreements allowing Ranbaxy and Watson to sell generic versions first. Teva, the world’s leading generic company by sales, wasn’t thought to be one of the first sellers, though it had reached some sort of agreement with Pfizer settling patent litigation that was expected to clear the way for generic Lipitor sales at a later date. Then this week, rumors began flying that Teva would be an early player. Had Teva reached a deal with Ranbaxy to sell Lipitor in the Indian company’s place? Was Teva
- Related Articles
- Sponsors
- Most Recent
- A Reader Recipe: Protein Coconut Macaroons
- A.M. Vitals: FCC Vote Could Boost Use of Wireless Medical Devices
- Nighttime Fasting: A New Way to Lose Weight?
- 5 Shorts For Your Summer Workouts
- Inversion Issues: How to Remedy Common Shoulderstand Complaints
- Don’t Be Shady! How to Choose the Right Sunglasses For Eye Health
- Sugar Shout Out: Who Will Land the Role of Christian Grey?
- It’s National Salad Month! Healthy Tips to Get You Excited
- Sugar Inc. Is Looking For 34 Awesome People!
- 6 Beach Workouts For a Sunny Memorial Day Weekend
- Must-Have Products to Keep Portions Under Control
- Fit Tip: Keep It Up Long After Summer Ends
- Stay Cool on the Run: Hydrate Your Head
- Berberine for Diabetes and Metabolic Syndrome
- Healthy Dose Link Time: Weight-Loss Success Stories From Women Like You
The world’s biggest selling drug of all time — the cholesterol medicine Lipitor — goes generic at the end of the month. Will the world’s leading maker of generic drugs be selling no-name Lipitor pills? A lot of tongues are wagging. Lipitor loses U.S. patent protection Nov. 30. Selling generic versions is a big prize, as world-wide brand sales top $10 billion a year. Pfizer plans to keep selling branded Lipitor. And it had reached agreements allowing Ranbaxy and Watson to sell generic versions first. Teva, the world’s leading generic company by sales, wasn’t thought to be one of the first sellers, though it had reached some sort of agreement with Pfizer settling patent litigation that was expected to clear the way for generic Lipitor sales at a later date. Then this week, rumors began flying that Teva would be an early player. Had Teva reached a deal with Ranbaxy to sell Lipitor in the Indian company’s place? Was Teva
See original here:
Pharma Mystery Theater: Teva and generic Lipitor
